Calliditas Therapeutics AB (publ)
CALT
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 38.54% | 38.17% | 48.40% | 177.75% | 183.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.54% | 38.17% | 48.40% | 177.75% | 183.81% |
| Cost of Revenue | 192.36% | 174.19% | 291.49% | 502.76% | 989.72% |
| Gross Profit | 33.63% | 34.66% | 43.69% | 171.81% | 177.26% |
| SG&A Expenses | 34.92% | 31.41% | 31.59% | 44.72% | 50.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 78.63% | -600.14% | -349.49% | -1,550.52% | -439,300.00% |
| Total Operating Expenses | 39.76% | 27.59% | 25.72% | 31.81% | 26.24% |
| Operating Income | -45.30% | -2.77% | 14.53% | 50.24% | 63.94% |
| Income Before Tax | -62.89% | -17.50% | -0.88% | 40.24% | 58.86% |
| Income Tax Expenses | 61.76% | 308.04% | 325.63% | 263.54% | 284.26% |
| Earnings from Continuing Operations | -62.86% | -28.37% | -2.37% | 36.71% | 57.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.86% | -28.37% | -2.37% | 36.76% | 57.28% |
| EBIT | -45.30% | -2.77% | 14.53% | 50.24% | 63.94% |
| EBITDA | -44.85% | -2.35% | 14.90% | 50.46% | 64.16% |
| EPS Basic | -62.77% | -27.76% | -0.66% | 38.00% | 58.09% |
| Normalized Basic EPS | -63.14% | -17.60% | -0.02% | 40.82% | 58.69% |
| EPS Diluted | -62.77% | -27.76% | -0.66% | 38.00% | 58.09% |
| Normalized Diluted EPS | -63.14% | -17.60% | -0.02% | 40.82% | 58.70% |
| Average Basic Shares Outstanding | 0.40% | 0.62% | 1.23% | 1.48% | 2.33% |
| Average Diluted Shares Outstanding | 0.40% | 0.62% | 1.23% | 1.48% | 2.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
